Language

Language

News

The IWMF is pleased to congratulate the 11 young investigators recognized at the 9th International Workshop on WM (IWWM9) on October 5-8, 2016, in Amsterdam, The Netherlands.

The Young Investigator Awards (YIAs) were established to encourage interest, knowledge, and skills in the study of WM by young medical specialists, researchers, and postdoctoral fellows, thereby continuing to stimulate research that will sustain and improve patients’ lives.

The eleven (11) recipients are the researchers and clinicians whose research abstracts were selected by the IWWM9 faculty(link is external).  The recognition of their work included participation in IWWM9, with funding provided by the IWMF, WM-Italy, and the European Waldenstrom Network.

The 2016 YIA recipients and the organizations funding their awards were:

IWWM9 YIA Awardees
Awardee Abstract Title Institution Country Funding Organization
Constance Baer

Constance Baer

MYD88 and CXCR4 analyses in lymphoplasmacytic lymphoma routine diagnostics need to consider mutations outside the L265P hotspot and follow-up testing MLL Munich Leukemia Laboratory, Munich Germany IWMF
George Chen

Acquisition of BTK C481S produces resistance to ibrutinib in MYD88 mutated WM and ABC DLBCL cells that is accompanied by ERK1/2 hyperactivation, and is targeted by the addition of the ERK1/2 inhibitor ulixertinib Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute USA IWMF
Eric Durot

Eric Durot

Retrospective analysis of 56 cases of transformed Waldenstrom macroglobulinemia. A study on behalf of the French Innovative Leukemia Organization (FILO) Department of Hematology, Centre Hospitalier Universitaire de Reims France IWMF
Simone Ferrero

Simone Ferrero

MYD88L265P mutation detection in Waldenström macroglobulinemia by droplet digital PCR: minimal residual disease monitoring and characterization on circulating free DNA Dept. of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Torino Italy IWMF
Maria Luisa Guerrera

M. L. Guerrara

Chromosome 6q deletions are common in Waldenström’s macroglobulinemia, and target regulatory genes for MYD88, CXCR4 and BCL2 signaling Fondazione IRCCS Policlinico San Matteo, Pavia Italy WM Italy
Joshua Gustine

Josh Guneits

The high risk for symptomatic hyperviscosity in patients with high serum IgM levels can be used to support initiation of treatment in Waldenstrom’s macroglobulinemia Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute USA IWMF
Shahrzad Jalali

Shahrzad Jalai

Identifying a role for PD-1/
PD-L1/PD-L2 signaling in Waldenstrom’s macroglobulinemia
Mayo Clinic, Rochester USA IWMF
Lisa Kaiser

L Kaiser

Characterization of endogenous CXCR4 inhibitory peptides to target Waldenstrom’s macroglobulinemia Institute of Experimental Cancer Research, University Hospital Ulm, Ulm Germany EWMn
Aneel Paulus

Aneel Paulus

Creation of Waldenstrom macroglobulinemia digital avatars using machine-learning and systems biology algorithms exposes novel and clinically relevant therapeutic opportunities Mayo Clinic, Jacksonville USA IWMF
Nickolas Tsakmaklis

Nickolas Tsakmaklis

Mutated MYD88 homozygosity is increased in previously treated patients with Waldenstrom’s macroglobulinemia, and associates with CXCR4 mutation status Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute USA IWMF
Josephine M. Vos

Josephine M. Vos

Prevalence of MYD88 L265P mutation in IgM anti-MAG peripheral neuropathy Antonius Ziekenhuis Nieuwegein (AZN), Nieuwegein and UMC Utrecht The Netherlands IWMF